There are lessons to learn from the first gene therapy for inherited retinal dystrophy patients with biallelic RPE65. For example, the PERCEIVE study provides important insights into the longer-term safety and efficacy of voretigene neparvovec in a real-world context [73]. The gene discussed is RPE65; the disease is inherited retinal dystrophy.